L-citrulline intravenous - Asklepion

Drug Profile

L-citrulline intravenous - Asklepion

Alternative Names: L-citrulline

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vanderbilt University
  • Developer Asklepion Pharmaceuticals; Vanderbilt University
  • Class Amino acids; Diamino amino acids
  • Mechanism of Action Amino acid replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute lung injury

Most Recent Events

  • 05 Jan 2018 Chemical structure information added
  • 26 Dec 2017 L-citrulline is still in phase III trials for Acute lung injury (In adolescents, In children, In infants, Prevention) in USA (IV)
  • 01 Aug 2016 Asklepion initiates enrolment in a phase III trial for Acute lung injury (In Infants, In children, In adolescents, Prevention) in USA (NCT02891837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top